Xenon Pharmaceuticals Announces At-The-Market Equity Offering
July 12 2018 - 7:00AM
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage
biopharmaceutical company, announced today that it has entered into
an at-the-market equity offering sales agreement with Jefferies and
Stifel, effective as of July 11, 2018, under which Xenon may sell
its common shares, from time to time, for up to $50.0 million in
aggregate sales proceeds in "at the market" transactions.
In connection with Xenon’s entry into the
at-the-market equity offering sales agreement, its prior
at-the-market equity offering sales agreement that it entered into
with Stifel on May 8, 2018 was mutually terminated by Xenon and
Stifel effective as of July 11, 2018.
A shelf registration statement on Form S-3
relating to the common shares offered in the at-the-market equity
offering described above was filed with the Securities and Exchange
Commission (SEC) on December 7, 2015 and declared effective by the
SEC on January 5, 2016. The offering is being made only by
means of a written prospectus and prospectus supplement that form a
part of the registration statement. A prospectus supplement
and accompanying prospectus relating to the offering have been
filed with the SEC and is available on the SEC's website at
www.sec.gov.
Copies of the prospectus supplement and
accompanying prospectus relating to these securities may also be
obtained by contacting Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, or by email at Prospectus_Department@Jefferies.com, or by
phone at (877) 821-7388; or from Stifel, Nicolaus & Company,
Incorporated, Attention: Prospectus Department, One Montgomery
Street, Suite 3700, San Francisco, CA 94104, by telephone at
415-364-2720 or by email at syndprospectus@stifel.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy the securities being
offered, nor may there be any sale of the securities being offered
in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any state or other
jurisdiction.
About Xenon Pharmaceuticals
Inc.
Xenon is a clinical stage biopharmaceutical
company focused on developing innovative therapeutics to improve
the lives of patients with neurological disorders.
Safe Harbor Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934 and
the Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. These forward-looking statements are not based on
historical fact, and include statements regarding our expectations
regarding our offering from time to time of our common shares
pursuant to the at-the-market equity offering sales agreement.
These forward-looking statements are based on current assumptions
that involve risks, uncertainties and other factors that may cause
the actual results, events or developments to be materially
different from those expressed or implied by such forward-looking
statements. These risks and uncertainties, many of which are beyond
our control, include, but are not limited to: promising results in
preclinical and early clinical trials may not be replicated in
subsequent clinical trials; clinical trials may not demonstrate
safety and efficacy of any of our or our collaborators' product
candidates; any of our or our collaborators' product candidates may
fail in development, may not receive required regulatory approvals,
or may be delayed to a point where they are not commercially
viable; we may not achieve additional milestones in our proprietary
or partnered programs; the impact of competition; adverse
conditions in the general domestic and global economic markets; as
well as the other risks identified in our filings with the
Securities and Exchange Commission and the securities commissions
in British Columbia, Alberta and Ontario. These forward-looking
statements speak only as of the date hereof and we assume no
obligation to update these forward-looking statements, and readers
are cautioned not to place undue reliance on such forward-looking
statements.
“Xenon” and the Xenon logo are registered
trademarks or trademarks of Xenon Pharmaceuticals Inc. in various
jurisdictions. All other trademarks belong to their respective
owner.
Investor/Media Contact:Jodi
Regts VP, Corporate Affairs & Investor Relations Xenon
Pharmaceuticals Inc. Phone: 604.484.3353 Email:
investors@xenon-pharma.com
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Apr 2023 to Apr 2024